The role of mesenchymal stem cell-derived extracellular vesicles in inflammation-associated programmed cell death
Source abstract
Abstract
Mesenchymal stem cells (MSCs), as a kind of pluripotent adult stem cell capable of exhibiting immunomodulatory properties, have been extensively studied in basic scientific research and clinical applications in inflammatory diseases. MSC-derived extracellular vesicles (MSC-EVs) are receiving increasingly attention as a major pathway for MSCs to exert intercellular communication. It has been demonstrated that programmed cell death (PCD) plays a critical role in the pathophysiology of human diseases, mainly including apoptosis, necroptosis, pyroptosis, ferroptosis, autophagy-dependent cell death, and other modalities. Recent studies have documented that MSCs are capable of regulating other types of PCD in addition to their antiapoptotic effects. Here, we review the potential influences of MSC-EVs on different types of PCD and diseases, categorize the differences in the therapeutic effects of MSC-EVs from various sources and interventional measures, compile the current research progress of PCD-related elements in clinical trials of MSC-EVs, and finally present the advantages and challenges of clinical applications of MSC-EVs. This review summarizes the updated advances in the regulation of inflammation-associated PCD by MSC-EVs, which are important for gaining insight into the molecular mechanisms and modulatory targets for inflammation-associated PCD.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Inflammasome and immune disorders · Biomarkers in Disease Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Building a consensus regarding the nature and origin of mesenchymal stem cells10.1002/jcb.10084 ↗
2. Mesenchymal stromal cells: current understanding and clinical status10.1002/stem.269 ↗
3. Sources and clinical applications of mesenchymal stem cells: state-of-the-art review10.18295/squmj.2018.18.03.002 ↗
4. Human mesenchymal stem cells - current trends and future prospective10.1042/BSR20150025 ↗
5. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement10.1080/14653240600855905 ↗
6. Hematopoietic stem cell heterogeneity takes center stage10.1016/j.stem.2012.05.006 ↗
7. Heterogeneity of young and aged murine hematopoietic stem cells revealed by quantitative clonal analysis using cellular barcoding10.1182/blood-2013-01-481135 ↗
8. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases10.1038/s41392-022-00932-0 ↗
9. Allogeneic mesenchymal stem cells stimulate cartilage regeneration and are safe for single-stage cartilage repair in humans upon mixture with recycled autologous chondrons10.1002/stem.2475 ↗
10. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment10.1016/j.bbrc.2007.01.045 ↗
11. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-610.1016/j.stem.2009.05.003 ↗
12. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation10.1016/j.ymthe.2006.05.016 ↗
13. Mesenchymal stem cell therapy in proteoglycan induced arthritis10.1136/annrheumdis-2013-204147 ↗
14. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics10.1161/CIRCRESAHA.108.187724 ↗
15. Kim · Nanomed. N. Engl. J. Med. · 2010 · 363 · 243410.1056/NEJMra0912273 ↗
16. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells10.1038/ncb1596 ↗
17. Glycosylation of extracellular vesicles: current knowledge, tools and clinical perspectives10.1080/20013078.2018.1442985 ↗
18. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 201810.1038/s41418-017-0012-4 ↗
19. Regulated cell death (RCD) in cancer: key pathways and targeted therapies10.1038/s41392-022-01110-y ↗
20. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics10.1038/bjc.1972.33 ↗
21. Molecular mechanisms of regulated necrosis10.1016/j.semcdb.2014.02.006 ↗
22. An apoptotic caspase network safeguards cell death induction in pyroptotic macrophages10.1016/j.celrep.2020.107959 ↗
23. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes10.4049/jimmunol.1302839 ↗
24. Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease10.1084/jem.20191644 ↗
25. ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages10.1038/s41598-018-21998-3 ↗
26. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection10.1073/pnas.1809548115 ↗
27. Dietary modulation of the microbiome affects autoinflammatory disease10.1038/nature13788 ↗
28. Manufacturing exosomes: a promising therapeutic platform10.1016/j.molmed.2018.01.006 ↗
29. A good manufacturing practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles10.1016/j.jcyt.2017.01.001 ↗
30. Exosome manufacturing status10.4155/fmc-2018-0417 ↗
31. Exosomes produced from 3D cultures of MSCs by tangential flow filtration show higher yield and improved activity10.1016/j.ymthe.2018.09.015 ↗
32. Engineering mesenchymal stem cells to improve their exosome efficacy and yield for cell-free therapy10.1080/20013078.2018.1522236 ↗
33. Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation10.1016/j.nano.2017.03.011 ↗
34. Freeze-dried and GMP-compliant pharmaceuticals containing exosomes for acellular mesenchymal stromal cell immunomodulant therapy10.2217/nnm-2018-0240 ↗
35. Scalable, cGMP-compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL-15/lactadherin complexes10.1080/20013078.2018.1442088 ↗
36. Practical considerations for translating mesenchymal stromal cell-derived extracellular vesicles from bench to bed10.3390/pharmaceutics14081684 ↗
37. Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform10.1002/sctm.18-0226 ↗
38. Application of mesenchymal stem cell-derived extracellular vesicles for stroke: biodistribution and microRNA study10.1007/s12975-018-0668-1 ↗
39. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery10.1016/j.addr.2012.07.001 ↗
40. Exosomes as immunotheranostic nanoparticles10.1016/j.clinthera.2014.04.019 ↗
41. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
42. Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way
43. To protect and to preserve: novel preservation strategies for extracellular vesicles10.3389/fphar.2018.01199 ↗
44. Targeting apoptosis in cancer therapy10.1038/s41571-020-0341-y ↗
45. Death by a thousand cuts: granzyme pathways of programmed cell death10.1146/annurev.immunol.26.021607.090404 ↗
46. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked10.1126/science.275.5303.1129 ↗
47. MOMP, cell suicide as a BCL-2 family business10.1038/cdd.2017.179 ↗
48. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c10.1016/S0092-8674(00)80085-9 ↗
49. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games10.1111/j.1365-2567.2005.02143.x ↗
50. The TNF and TNF receptor superfamilies: integrating mammalian biology10.1016/S0092-8674(01)00237-9 ↗
51. Regulated cell death: signaling and mechanisms10.1146/annurev-cellbio-100913-013226 ↗
52. The TRAIL apoptotic pathway in cancer onset, progression and therapy10.1038/nrc2465 ↗
53. PINK1 contained in huMSC-derived exosomes prevents cardiomyocyte mitochondrial calcium overload in sepsis via recovery of mitochondrial Ca(2+) efflux10.1186/s13287-021-02325-6 ↗
54. Bone marrow-mesenchymal stem cell-derived exosomal microRNA-141 targets PTEN and activates β-catenin to alleviate myocardial injury in septic mice10.1080/08923973.2021.1955920 ↗
55. Exosomal miR-223 contributes to mesenchymal stem cell-elicited cardioprotection in polymicrobial sepsis10.1038/srep13721 ↗
56. Mesenchymal stem cells-derived exosomes prevent sepsis-induced myocardial injury by a CircRTN4/miR-497-5p/MG53 pathway10.1016/j.bbrc.2022.05.094 ↗
57. Exosomes from adipose tissue-derived mesenchymal stem cells ameliorate histone-induced acute lung injury by activating the PI3K/Akt pathway in endothelial cells10.1186/s13287-020-02015-9 ↗
58. Exosomes derived from ADSCs attenuate sepsis-induced lung injury by delivery of Circ-Fryl and regulation of the miR-490-3p/SIRT3 pathway10.1007/s10753-021-01548-2 ↗
59. Exosomal lncRNA-p21 derived from mesenchymal stem cells protects epithelial cells during LPS-induced acute lung injury by sponging miR-18110.1093/abbs/gmab043 ↗
60. Human umbilical cord mesenchymal stem cell exosomes alleviate sepsis-associated acute kidney injury via regulating microRNA-146b expression10.1007/s10529-020-02831-2 ↗
61. Bone mesenchymal stem cell-derived extracellular vesicles inhibit DAPK1-mediated inflammation by delivering miR-191 to macrophages10.1016/j.bbrc.2022.02.009 ↗
62. Mesenchymal stem cells-derived extracellular vesicles carrying microRNA-17 inhibits macrophage apoptosis in lipopolysaccharide-induced sepsis10.1016/j.intimp.2021.107408 ↗
63. Exosomal miR-21 secreted by IL-1beta-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis10.1016/j.lfs.2020.118658 ↗
64. Inflammasomes: mechanism of assembly, regulation and signalling10.1038/nri.2016.58 ↗
65. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity10.1084/jem.20172222 ↗
66. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux10.1002/eji.201545772 ↗
67. Inflammatory caspases are innate immune receptors for intracellular LPS10.1038/nature13683 ↗
68. Non-canonical inflammasome activation targets caspase-1110.1038/nature10558 ↗
69. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death10.1038/nature15514 ↗
70. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling10.1038/nature15541 ↗
71. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin10.1038/nature22393 ↗
72. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death10.1038/ncomms14128 ↗
73. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death10.1126/science.aau2818 ↗
74. GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever10.1084/jem.20172060 ↗
75. Nlrp3 inflammasome activation and Gasdermin D-driven pyroptosis are immunopathogenic upon gastrointestinal norovirus infection10.1371/journal.ppat.1007709 ↗
76. Mesenchymal stem cells-derived extracellular vesicles-shuttled microRNA-223-3p suppress lipopolysaccharide-induced cardiac inflammation, pyroptosis, and dysfunction10.1016/j.intimp.2022.108910 ↗
77. Exosomes derived from mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through inhibiting pyroptosis10.2147/DDDT.S239546 ↗
78. Extracellular vesicles from anoxia preconditioned mesenchymal stem cells alleviate myocardial ischemia/reperfusion injury10.18632/aging.202611 ↗
79. LncRNA XIST shuttled by adipose tissue-derived mesenchymal stem cell-derived extracellular vesicles suppresses myocardial pyroptosis in atrial fibrillation by disrupting miR-214-3p-mediated Arl2 inhibition10.1038/s41374-021-00635-0 ↗
80. LncRNA KLF3-AS1 in human mesenchymal stem cell-derived exosomes ameliorates pyroptosis of cardiomyocytes and myocardial infarction through miR-138-5p/Sirt1 axis10.1186/s13287-019-1522-4 ↗
81. BMSC-derived exosomes ameliorate osteoarthritis by inhibiting pyroptosis of cartilage via Delivering miR-326 Targeting HDAC3 and STAT1//NF-kappaB p65 to chondrocytes10.1155/2021/9972805 ↗
82. Engineering extracellular vesicles restore the impaired cellular uptake and attenuate intervertebral disc degeneration10.1021/acsnano.1c04514 ↗
83. Mesenchymal stem cells-derived exosomes ameliorate intervertebral disc degeneration through inhibiting pyroptosis10.1111/jcmm.15784 ↗
84. Stem cell-derived exosomes prevent pyroptosis and repair ischemic muscle injury through a novel exosome/circHIPK3/ FOXO3a pathway10.7150/thno.42259 ↗
85. Human umbilical cord mesenchymal stem cells deliver exogenous miR-26a-5p via exosomes to inhibit nucleus pulposus cell pyroptosis through METTL14/NLRP310.1186/s10020-021-00355-7 ↗
86. Huc-MSCs-derived exosomes attenuate inflammatory pain by regulating microglia pyroptosis and autophagy via the miR-146a-5p/TRAF6 axis10.1186/s12951-022-01522-6 ↗
87. Bone marrow mesenchymal stem cells-derived exosomes containing miR-539-5p inhibit pyroptosis through NLRP3/caspase-1 signalling to alleviate inflammatory bowel disease10.1007/s00011-022-01577-z ↗
88. hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis10.1186/s13287-021-02492-6 ↗
89. ADMSC Exo-MicroRNA-22 improve neurological function and neuroinflammation in mice with Alzheimer's disease10.1111/jcmm.16787 ↗
90. MSC derived EV loaded with miRNA-22 inhibits the inflammatory response and nerve function recovery after spinal cord injury in rats10.1111/jcmm.16965 ↗
91. Bone mesenchymal stem cells-derived miR-223-3p-containing exosomes ameliorate lipopolysaccharide-induced acute uterine injury via interacting with endothelial progenitor cells10.1080/21655979.2021.2001185 ↗
92. Bone marrow-derived mesenchymal stem cells microvesicles stabilize atherosclerotic plaques by inhibiting NLRP3-mediated macrophage pyroptosis10.1002/cbin.11526 ↗
93. Exosomal miR-17-5p from adipose-derived mesenchymal stem cells inhibits abdominal aortic aneurysm by suppressing TXNIP-NLRP3 inflammasome10.1186/s13287-022-03037-1 ↗
94. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death10.1021/acschembio.5b00245 ↗
95. Ferroptosis: mechanisms, biology and role in disease10.1038/s41580-020-00324-8 ↗
96. Emerging mechanisms and disease relevance of ferroptosis10.1016/j.tcb.2020.02.009 ↗
97. Ferroptosis: molecular mechanisms and health implications10.1038/s41422-020-00441-1 ↗
98. Ferroptosis in infection, inflammation, and immunity10.1084/jem.20210518 ↗
99. Role of mitochondria in ferroptosis10.1016/j.molcel.2018.10.042 ↗
100. The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma10.1016/j.celrep.2019.07.107 ↗